Efficacy and safety of midazolam and vesparax in treatment of sleep disorders.

Publisher Website
Google Scholar
Abstract
In a double-blind parallel study in which a placebo phase preceded and followed the double-blind verum phase, midazolam 15 mg and Vesparax (150 mg secobarbital, 50 mg brallobarbital, 50 mg hydroxyzine) were administered to 30 female patients aged 20-76 yr, suffering from insomnia secondary to neuromuscular disease. Both products were efficient hypnotics maintaining a constant level of effect. Midazolam was better tolerated and, in contrast to Vesparax, did not cause hangover, nor did rebound phenomena ensue after its withdrawal.